First Tracks Biotherapeutics screens with attractive valuation and strong price momentum, but weak business quality and extreme insider selling are significant red flags that warrant exiting the position.
Thesis pillars
- Value Trap Margin Compression↓Deteriorating
- Extreme Insider Selling→Stable
- Quality Below Engine Floor→Stable
- +1 more pillar — see the Why tab for full reasoning
First Tracks Biotherapeutics, I (TRAX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $36.54: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 27.67; Below-average business quality; Negative price momentum.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta... Read more
Sell if holding. Engine safety override at $36.54: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 27.67; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-09-13Recent Developments — First Tracks Biotherapeutics, I
Latest news
- NEWS HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $57 Price Target — benzinga Sep 3, 2026 neutral
- NEWS Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday — benzinga Sep 2, 2026 positive
- NEWS Barclays Maintains Overweight on First Tracks, Raises Price Target to $65 — benzinga Aug 13, 2026 neutral
- NEWS First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results — benzinga Aug 13, 2026 positive
- NEWS Wedbush Maintains Outperform on First Tracks, Raises Price Target to $70 — benzinga Aug 13, 2026 positive
Generated 2026-09-14T05:29:00Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Volatile — 8.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $36.54: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 27.67; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $34.43. Score 5.4/10, moderate confidence.
Take-profit target: $60.42 (+65.8% upside). Prior stop was $34.43. Stop-loss: $34.43.
Quality below floor (2.5 < 4.0).
First Tracks Biotherapeutics, I trades at a P/E of N/A (forward -9.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover TRAX with a consensus score of 4.3/5. Average price target: $69.
What does First Tracks Biotherapeutics, I do?First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology...
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.